- Home
- ROIV vs CRDO Comparison
ROIV vs CRDO Comparison
Compare ROIV & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CRDO |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United Kingdom | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 38.2B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CRDO |
|---|---|---|
| Price | $28.89 | $220.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $28.94 | ★ $179.62 |
| AVG Volume (30 Days) | 6.2M | ★ 7.3M |
| Earning Date | 05-28-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 261.11 |
| EPS | N/A | ★ 1.62 |
| Revenue | $8,260,000.00 | ★ $436,775,000.00 |
| Revenue This Year | N/A | $210.92 |
| Revenue Next Year | $744.61 | $57.22 |
| P/E Ratio | ★ N/A | $127.71 |
| Revenue Growth | N/A | ★ 126.34 |
| 52 Week Low | $10.71 | $66.75 |
| 52 Week High | $32.79 | $245.95 |
Technical Indicators
Market Signals| Indicator | ROIV | CRDO |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 59.30 |
| Support Level | $26.95 | $132.85 |
| Resistance Level | $30.10 | N/A |
| Average True Range (ATR) | 1.09 | 22.11 |
| MACD | -0.16 | -1.04 |
| Stochastic Oscillator | 18.51 | 74.92 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.